Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

The State of Comparative Effectiveness Research and the Environment for Decision-Making (2011)

Comparative effectiveness research (CER) has gained in national prominence in recent years through an infusion of federal funds and passage of the Patient Protection and Affordable Care Act (PPACA), which established the non-profit Patient-Centered Outcomes Research Institute (PCORI) to oversee this important research.  Although PPACA is still facing challenges in the courts and Congress, many provisions of the law, including the establishment of PCORI, are already being implemented. While this foundational work is underway, the National Pharmaceutical Council, working with the public health research firm Social & Scientific Systems (SSS), examined the environment for health care decisions, especially the current state of CER and its impact on medical decision-making.

The purpose was to set a baseline for where key stakeholders believe we are today on CER and for tracking progress and judging future effects. According to the findings, there is clear recognition among key health care influentials about the importance of CER and its promise for the future. These stakeholders also expressed tempered optimism about progress in efforts to provide or improve the tools necessary for this research, and that any significant effects of CER are yet to be realized, and much work remains to be done.

CER Survey Highlights:

CER has “arrived” as a key issue in the health care conversation.

  • Nearly 6 in 10 of survey respondents were “very familiar” with comparative effectiveness research and about 30 percent of respondents were “somewhat familiar” with CER
  • CER was cited as “very important” to three-quarters of respondents or their organizations
  • Roughly one-third were “very familiar” with the Patient-Centered Outcomes Research Institute

Stakeholders feel we are moving gradually, but in the right direction, in establishing CER.

  • Respondents acknowledge that there is a greater availability of research methods and standards, as well as improvements in research priorities addressing treatment choices faced by patients and providers.
  • Respondents felt there was increasing movement from solely considering clinical effectiveness to evaluating a fuller picture of quality of life, workplace productivity effects, quality of care and the potential for improved adherence to treatments.

Stakeholders feel that over time CER will likely improve health care; however changes have not substantially taken root yet and the full impact may require significantly more time.

  • Only 30 percent believed that CER would lead to moderate improvements in health care decision-making in the next year.

Stakeholders recognize the key players on CER

  • Overwhelmingly, surveyed stakeholders believe that AHRQ will continue to play a significant role in CER during the next five years, particularly in the development of research standards (78 percent) and priorities (74 percent), with NIH (64 percent; 69 percent) and PCORI (50 percent; 63 percent) also taking an active role.
  • PCORI’s slightly lower positioning on establishing research standards may reflect the newness of the organization and its need to communicate goals and mission to audiences.

Respondents have clear expectations on the entities that will fund and conduct CER

  • Survey respondents said that the role of funding CER fell most significantly to NIH (81 percent), AHRQ (74 percent), and the pharmaceutical and medical products industry (68 percent).
  • In terms of conducting CER, respondents overwhelmingly pointed to academia (85 percent) as the main driver, followed by the pharmaceutical/medical products industry (62 percent).

CER Survey Parameters:

The survey, conducted from November 2010-March 2011, targeted key stakeholders who have an impact on, or are affected by, research involving medical effectiveness, including government, researchers, insurers, employers, human resource consultants and healthcare coalitions, and trade and other groups. A total of 118 stakeholders participated.

Survey materials:

Blog Post

CER Tweets of the Week (April 7-11, 2014)

Collaboration was a popular topic among comparative effectiveness research (CER) stakeholders on Twitter this week. They tweeted about the National...
YouTube Videos

Webinar: CER Collaborative: Tools You Can Use

Collaborative members hosted a webinar explaining how to use the tools they developed to create greater uniformity and transparency when evaluating...
Blog Post

CER Tweets of the Week (March 31- April 4, 2014)

This week, health care stakeholders on Twitter highlighted the many activities and sessions at the Academy of Managed Care Pharmacy’s (AMCP) 26th...
Blog Post

4/8 Webinar on CER Collaborative: Tools You Can Use

The CER Collaborative--a group formed by the Academy of Managed Care Pharmacy (AMCP), the International Society for Pharmacoeconomics and Outcomes...
Press Release

CER Collaborative Improving Health Outcomes Through New Comparative Evidence Tools

(Washington, DC, March 24, 2014)—Three peer-reviewed articles published in Value in Health offer important guidance to aid formulary decision-makers...
Press Release

Eli Lilly and Company Joins the National Pharmaceutical Council

Washington, D.C. (January 22, 2014)—The National Pharmaceutical Council (NPC) today announced that Eli Lilly and Company has joined the health care...
Press Release

Boehringer Ingelheim’s Jeff Huth Elected as National Pharmaceutical Council’s Chairman of the Board

Washington, DC (November 8, 2013)--The National Pharmaceutical Council (NPC) today announced that Jeff Huth, Senior Vice President, Managed Markets,...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
Commentary and Testimony Page

Living Up to Its Name? The Role of Patient-Centered Research

Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...
YouTube Videos

Webinar: CER Collaborative: Tools You Can Use

Collaborative members hosted a webinar explaining how to use the tools they developed to create greater uniformity and transparency when evaluating...
YouTube Videos

Engaging Patients in Research

National Pharmaceutical Council President Dan Leonard explains why it's important to include patients throughout the research process. He says that...
YouTube Videos

Patient Input on What Makes Comparative Effectiveness Research Useful

Myrl Weinberg, chief executive officer of the National Health Council, says that many patients are still concerned about how comparative...
YouTube Videos

Developing Usability Criteria for Comparative Effectiveness Research

Avalere Health Senior Manager Sung Hee Choe outlines her work with the National Health Council to bring stakeholders together to develop the criteria...
Blog Post

CER Tweets of the Week (April 7-11, 2014)

Collaboration was a popular topic among comparative effectiveness research (CER) stakeholders on Twitter this week. They tweeted about the National...
Blog Post

CER Tweets of the Week (March 31- April 4, 2014)

This week, health care stakeholders on Twitter highlighted the many activities and sessions at the Academy of Managed Care Pharmacy’s (AMCP) 26th...
Blog Post

4/8 Webinar on CER Collaborative: Tools You Can Use

The CER Collaborative--a group formed by the Academy of Managed Care Pharmacy (AMCP), the International Society for Pharmacoeconomics and Outcomes...
Blog Post

CER Collaborative Rolls Out New Resources to Aid Formulary Decision-Making

A newly published series of peer-reviewed articles developed by the CER Collaborative will help formulary decision-makers more effectively evaluate...

Research

National Pharmaceutical Council 2013 Annual Report

The 2013 Annual Report highlights NPC's research, educational and partnership activities throughout...
  •  
  • 1 of 12
  • >

Commentary & Testimony